Evidence map›Paper›PMID 37127835›Full record

ReviewPlant cell reports2023

Plastid engineering using episomal DNA.

Alessandro Occhialini, Scott C Lenaghan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Plant cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Alessandro OcchialiniDepartment of Plant Sciences, University of Tennessee, 112 Plant Biotechnology Building 2505 E J Chapman Drive, Knoxville, TN, 37996, USA. aocchial@utk.edu.ORCID http://orcid.org/0000-0002-1162-798X
Scott C LenaghanCenter for Agricultural Synthetic Biology (CASB), University of Tennessee, 2640 Morgan Circle Drive, Knoxville, TN, 37996, USA. slenagha@utk.edu.ORCID http://orcid.org/0000-0002-7539-1726
University of Tennessee at Knoxville · US

Funding

National Institute of Food and Agriculture 2022-33522-38289
6 · The paper itself

Abstract

key messageNovel episomal systems have the potential to accelerate plastid genetic engineering for application in plant synthetic biology. Plastids represent valuable subcellular compartments for genetic engineering of plants with intrinsic advantages to engineering the nucleus. The ability to perform site-specific transgene integration by homologous recombination (HR), coordination of transgene expression in operons, and high production of heterologous proteins, all make plastids an attractive target for synthetic biology. Typically, plastid engineering is performed by homologous recombination; however, episomal-replicating vectors have the potential to accelerate the design/build/test cycles for plastid engineering. By accelerating the timeline from design to validation, it will be possible to generate translational breakthroughs in fields ranging from agriculture to biopharmaceuticals. Episomal-based plastid engineering will allow precise single step metabolic engineering in plants enabling the installation of complex synthetic circuits with the ambitious goal of reaching similar efficiency and flexibility of to the state-of-the-art genetic engineering of prokaryotic systems. The prospect to design novel episomal systems for production of transplastomic marker-free plants will also improve biosafety for eventual release in agriculture.

Indexed as

Genetic EngineeringPlastidsDNAMetabolic EngineeringPlantsPlants, Genetically ModifiedTransformation, GeneticTransgenesDNAChloroplast oriEpisomal replicationGeminivirus Rep systemMinichromosomeMini-synplastomePlastid engineering

Identifiers

PMID37127835
OpenAlexW4367669462

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.